An open-label, randomized, phase 3 trial of intravenous temsirolimus (CCI-779) at two dose levels compared to investigator's choice therapy in relapsed, refractory subjects with mantle cell lymphoma (MCL).

Trial Profile

An open-label, randomized, phase 3 trial of intravenous temsirolimus (CCI-779) at two dose levels compared to investigator's choice therapy in relapsed, refractory subjects with mantle cell lymphoma (MCL).

Completed
Phase of Trial: Phase III

Latest Information Update: 06 Jul 2013

At a glance

  • Drugs Temsirolimus (Primary)
  • Indications Mantle-cell lymphoma
  • Focus Adverse reactions; Pharmacogenomic; Registrational; Therapeutic Use
  • Acronyms OPTIMAL
  • Sponsors Pfizer
  • Most Recent Events

    • 21 Jan 2011 Additional lead trial centre identified as reported by ClinicalTrials.gov.
    • 21 Jan 2011 Additional lead trial centre identified as reported by ClinicalTrials.gov.
    • 21 Jan 2011 Additional trial location (Brazil) identified as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top